What's the most recent regulatory action in Clostridium Perfringens Empyema?

Most recent: Cleocin T — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/clostridium-perfringens-empyema.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Clostridium Perfringens Empyema — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clostridium Perfringens Empyema (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Clostridium Perfringens Empyema, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cleocin T	CLINDAMYCIN PHOSPHATE	Pfizer	Lincosamide Antibacterial		1972-01-01
Cleocin	clindamycin	Generic (originally Upjohn/Pfizer)	Lincosamide antibiotic	50S ribosomal protein L10	1970-01-01
Penicillin G Potassium In Plastic Container	Benzylpenicillin	Pfizer	Penicillin-class Antibacterial		1947-01-01
penicillin	penicillin	Karlstad University		Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-23 — Cleocin T · FDA · approved · US
2026-03-18 — Cleocin T · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Clostridium Perfringens Empyema
Generic (originally Upjohn/Pfizer) · 1 drug in Clostridium Perfringens Empyema
Karlstad University · 1 drug in Clostridium Perfringens Empyema

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Clostridium Perfringens Empyema:

Cite this brief

Drug Landscape (2026). Clostridium Perfringens Empyema — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/clostridium-perfringens-empyema. Accessed 2026-06-10.

Clostridium Perfringens Empyema full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing